MXPA05011371A - Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada. - Google Patents

Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.

Info

Publication number
MXPA05011371A
MXPA05011371A MXPA05011371A MXPA05011371A MXPA05011371A MX PA05011371 A MXPA05011371 A MX PA05011371A MX PA05011371 A MXPA05011371 A MX PA05011371A MX PA05011371 A MXPA05011371 A MX PA05011371A MX PA05011371 A MXPA05011371 A MX PA05011371A
Authority
MX
Mexico
Prior art keywords
individuals
renal function
impaired renal
diuresis
improved
Prior art date
Application number
MXPA05011371A
Other languages
English (en)
Spanish (es)
Inventor
Dittrich Howard
Original Assignee
Novacardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacardia Inc filed Critical Novacardia Inc
Publication of MXPA05011371A publication Critical patent/MXPA05011371A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA05011371A 2003-04-25 2004-04-23 Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada. MXPA05011371A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46600703P 2003-04-25 2003-04-25
PCT/US2004/012518 WO2004096228A1 (en) 2003-04-25 2004-04-23 Method of improved diuresis in individuals with impaired renal function

Publications (1)

Publication Number Publication Date
MXPA05011371A true MXPA05011371A (es) 2005-12-01

Family

ID=33418325

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011371A MXPA05011371A (es) 2003-04-25 2004-04-23 Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.

Country Status (16)

Country Link
US (3) US7579331B2 (enExample)
EP (1) EP1620107A1 (enExample)
JP (1) JP2006524699A (enExample)
KR (1) KR20060004959A (enExample)
CN (1) CN1859913A (enExample)
AR (1) AR044069A1 (enExample)
AU (1) AU2004233852A1 (enExample)
BR (1) BRPI0409699A (enExample)
CA (1) CA2522971A1 (enExample)
MX (1) MXPA05011371A (enExample)
NO (1) NO20055536L (enExample)
NZ (1) NZ543109A (enExample)
RU (1) RU2367442C2 (enExample)
TW (1) TW200500070A (enExample)
WO (1) WO2004096228A1 (enExample)
ZA (1) ZA200509311B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
BRPI0409699A (pt) 2003-04-25 2006-04-18 Novacardia Inc métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
US20070238740A1 (en) * 2003-08-28 2007-10-11 Nitromed, Inc. Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
EP1755594A1 (en) * 2004-04-16 2007-02-28 Novacardia, Inc. Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
US7396829B2 (en) * 2005-02-24 2008-07-08 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
CN101166515A (zh) * 2005-04-22 2008-04-23 美国诺华卡迪亚公司 用于非水溶性药物成分静脉注射的乳剂的生产
EP1961422A1 (en) * 2005-12-14 2008-08-27 Kyowa Hakko Kogyo Co., Ltd. Easily absorbed oral preparation containing xanthine derivative
AU2007235372A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine A1 receptor antagonists and anticonvulsants
CN101466435A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 Kw-3902在充血性心脏衰竭和急性体液超负荷患者中实现利尿作用的用途
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416810C (sv) 1977-10-14 1982-07-19 Draco Ab Forfarande for framstellning av xantinderivat med antiallergisk aktivitet
FR2531085A1 (fr) 1982-07-28 1984-02-03 Adir Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4769377A (en) * 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
SE9000207L (sv) 1990-01-22 1991-07-23 Nobel Chemicals Ab Laekemedel samt anvaendningen av detsamma
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
WO1993000081A1 (en) 1991-06-28 1993-01-07 Sepracor, Inc. Optically pure s(-) nadolol for treatment of cardiovascular disorders
CA2093403C (en) 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
TW252044B (enExample) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
DE4238367A1 (de) * 1992-11-13 1994-05-19 Boehringer Ingelheim Kg Diuretisches Mittel
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
CN1049117C (zh) 1994-09-16 2000-02-09 赵明玉 预防和治疗偏头痛的偏头痛片
ES2199289T3 (es) * 1995-07-26 2004-02-16 Kyowa Hakko Kogyo Co., Ltd. Dispersion solida de derivados de xantina.
DK0958821T3 (da) * 1996-08-07 2005-01-03 Kyowa Hakko Kogyo Kk Fedtemulsion, der indeholder xanthinderivat
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
DE19816857A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20020115687A1 (en) 1998-04-24 2002-08-22 Evan Beckman Method and composition for restoring diuretic and renal function
ES2211079T3 (es) * 1998-04-24 2004-07-01 Cv Therapeutics Composicion que contiene un antagonista del receptor a1 de adenosina y metodo para restablecer la funcion diuretica y renal.
EP0970696A1 (en) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
ES2323357T3 (es) * 1999-11-12 2009-07-14 Biogen Idec Ma Inc. Policicloalquilpurinas como antagonistas del receptor de adenosina.
EE200200248A (et) * 1999-11-12 2003-06-16 Biogen, Inc. Adenosiini retseptori antagonistid ja nende valmistamise ja kasutamise meetodid
US20050038017A1 (en) * 1999-12-22 2005-02-17 Wolff Andrew A. Method and composition for restoring diuretic and renal function
UA75625C2 (en) * 2000-12-01 2006-05-15 Biogen Inc Condensed purine derivatives as a1 adenosine receptor antagonists
HUP0302455A3 (en) 2000-12-18 2005-05-30 Novartis Ag Combination pharmaceutical compositions containing amplodipine and benazepril and their use
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
BRPI0409699A (pt) * 2003-04-25 2006-04-18 Novacardia Inc métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
EP1755594A1 (en) * 2004-04-16 2007-02-28 Novacardia, Inc. Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
WO2005105803A2 (en) * 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
AU2007235372A1 (en) 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine A1 receptor antagonists and anticonvulsants
CN101466383A (zh) 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
CN101466435A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 Kw-3902在充血性心脏衰竭和急性体液超负荷患者中实现利尿作用的用途
WO2008024277A2 (en) * 2006-08-22 2008-02-28 Novacardia, Inc. Kw-3902 conjugates that do not cross the blood-brain barrier

Also Published As

Publication number Publication date
US20060030572A1 (en) 2006-02-09
NZ543109A (en) 2008-06-30
KR20060004959A (ko) 2006-01-16
US20050004145A1 (en) 2005-01-06
AU2004233852A1 (en) 2004-11-11
US20060035911A1 (en) 2006-02-16
RU2005131938A (ru) 2006-06-27
ZA200509311B (en) 2006-10-25
CN1859913A (zh) 2006-11-08
AR044069A1 (es) 2005-08-24
US7579331B2 (en) 2009-08-25
RU2367442C2 (ru) 2009-09-20
TW200500070A (en) 2005-01-01
NO20055536D0 (no) 2005-11-23
WO2004096228A1 (en) 2004-11-11
CA2522971A1 (en) 2004-11-11
JP2006524699A (ja) 2006-11-02
BRPI0409699A (pt) 2006-04-18
EP1620107A1 (en) 2006-02-01
NO20055536L (no) 2005-12-29

Similar Documents

Publication Publication Date Title
WO2007149285A3 (en) Method of improved diuresis in individuals with impaired renal function
TW200500070A (en) Method of improved diuresis in individuals with impaired renal function
WO2003026591A3 (en) Modification of feeding behavior
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
DK1416842T3 (da) Farmaceutiske kombinationer af oxycodon og naloxon
WO2003057235A3 (en) Modification of feeding behavior
ATE374016T1 (de) Tablette mit hohem wirkstoffgehalt
ATE431738T1 (de) Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
AU2003243551A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
EP1711207A4 (en) INTERFERON ALPHA ANTIBODIES AND ITS USES
WO2004000354A3 (en) Method of treating the syndrome of lipodystrophy
AR042534A1 (es) Formas de dosificacion que comprenden un inhibidor de la proteina de transferencia de esteres de colesterilo (ptec) y un inhibidor de la 3-hidroxi-3-metil glutaril-coenzima a (hmg-co-a) reductasa
FR2850377B1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
WO2004012762A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
IL162768A0 (en) Method of treatment of a patient requiring analgesia
NO20051658L (no) Terapeutisk behandling
CY1109215T1 (el) Συστημα χορηγησης οπιοειδους
DK1537132T3 (da) Salt af mortin-6-glucuronid
AU2003248893A1 (en) Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias
AU2003221289A1 (en) An artificial low toxicity tobacco base and a method using the tobacco base
EP1314423A4 (en) MEDICAL CONNECTIONS
RU2002113945A (ru) Способ создания "новокаиновой подушки" для микросклерозирования
AU2003261011A1 (en) Combined casual and training footwear
ITMI20030317A1 (it) Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
FR2840899B1 (fr) Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique

Legal Events

Date Code Title Description
FA Abandonment or withdrawal